Amneal Pharmaceuticals
AMRX71
$8.47arrow_drop_down5.77%-$0.51
High Growth
AMRX71
$8.47
arrow_drop_down5.77%Performance History
| Key Stats | |
|---|---|
| Open | $9.00 |
| Prev. Close | $9.00 |
| EPS | -0.81 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 8.33 | 9.22 |
| 52 Week Range | 3.36 | 9.46 |
| Ratios | |
|---|---|
| EPS | -0.81 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Amneal Pharmaceuticals (AMRX)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. Chirag K. Patel
- Headquarters
- Bridgewater
- Employees
- 7600
- Exchange
- NYSE
Keep an eye on Amneal Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Amneal Pharmaceuticals 's (AMRX) price per share?
The current price per share for Amneal Pharmaceuticals (AMRX) is $8.47. The stock has seen a price change of -$0.52 recently, indicating a -5.78% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Amneal Pharmaceuticals (AMRX)?
For Amneal Pharmaceuticals (AMRX), the 52-week high is $9.46, which is 11.75% from the current price. The 52-week low is $3.36, the current price is 152.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Amneal Pharmaceuticals (AMRX) a growth stock?
Amneal Pharmaceuticals (AMRX) has shown an average price growth of -6.65% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Amneal Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Amneal Pharmaceuticals (AMRX) stock price performance year to date (YTD)?
As of the latest data, Amneal Pharmaceuticals (AMRX) has a year-to-date price change of 41.64%. Over the past month, the stock has experienced a price change of -2.64%. Over the last three months, the change has been 5.35%. Over the past six months, the figure is 25.48%. Looking at a longer horizon, the five-year price change stands at 199.29%.
help
Is Amneal Pharmaceuticals (AMRX) a profitable company?
Amneal Pharmaceuticals (AMRX) has a net income of -$48.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 34.28% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 12.5% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.39B, with a revenue growth rate of 8.2%, providing insight into the company's sales performance and growth. The gross profit is $820.56M. Operating income is noted at $204.37M. Furthermore, the EBITDA is $472.06M.
help
What is the market capitalization of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals (AMRX) has a market capitalization of $2.62B. The average daily trading volume is 8.52, indicating the stock's liquidity and investor engagement.
News
OPIOID OVERDOSE
BRAIN FUNCTIONING
TREATMENT OPTIONS
MARKET ANALYSIS
Opioid Overdose Treatment Market is Projected to Reach US$ 3.1 Billion by 2034 | Fact.MR Report
SPECIALTY PHARMA
TEVA
ORGANON
VIATRIS
PERRIGO
AMPHASTAR PHARMACEUTICALS
AMNEAL PHARMACEUTICALS
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
SOLID ORGAN TRANSPLANT
ORGAN TRANSPLANT
ORGAN FAILURE
MEDICAL ADVANCEMENTS
Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report
PERICARDITIS
CARDIAC DISORDERS
ANTI-INFLAMMATORY DRUGS
GENERICS
Pericarditis Drugs Global Strategic Business Report 2023-2030: Patent Expiries and Surge of Generics in the Market, Increasing Incidence of Cardiac Disorders Driving Demand
ANALYST RATINGS
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
May 3, 2024
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall